Reflections on TORCH: Potential Mechanisms for the Survival Benefit of Salmeterol/Fluticasone Propionate in COPD Patients

REFERENCES

• Pauwels R A, Buist A S, Calverley P M, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD). Am J Respir Crit Care Med 2001; 163: 1256–1276
   PubMedGoogle Scholar
• Murray C J, Lopez A D. Alternative projections of mortality and disability by cause 1990–2006: Global Burden of Disease Study. Lancet 1997; 349: 1498–1504
   PubMed Web of Science ®Google Scholar
• Ferlay J, et al. Globocan 2002, Cancer Incidence, mortality and prevalence worldwide. IARC press, Lyon 2004
   Google Scholar
• Mannino D, Homa D M, Akinbami L J, et al. Chronic obstructive pulmonary disease surveillance–United States 1971–2000. In Surveillance Summaries MMWR 2002; 51: 1–16
   PubMed Web of Science ®Google Scholar
• DeMarco R, Accordini S, Cerveri I, et al. An international survey of Chronic Obstructive Pulmonary Disease in young patients according to GOLD stages. Thorax 2004; 59: 120–125
   PubMed Web of Science ®Google Scholar
• Anthonisen N R, et al. The effects of a smoking cessation intervention on 14.5 year mortality: a randomised clinical trial. Ann Intern Med 2005; 142: 233–239
   PubMed Web of Science ®Google Scholar
• Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease. Ann Intern Med 1980; 93: 391–398
   PubMed Web of Science ®Google Scholar
• Fishman A, Martinez F, Naunheim K, et al. A randomised trial comparing lung-volume–reduction surgery with medical therapy for severe emphysema. New Engl J Med 2003; 348: 2059–2073
   PubMed Web of Science ®Google Scholar
• Calverley P MA, Anderson J A, Celli B, et al. Salmeterol and fluticasone propionate and survival in Chronic Obstructive Pulmonary Disease. N Engl J Med 2007; 356: 775–789
   PubMed Web of Science ®Google Scholar
• Celli B R, Thomas N E, Anderson J A, et al. Effect of pharmacotherapy on rate of decline of lung function in COPD: Results from the TORCH study. Am J Respir Crit Care Med 2008; 178: 332–338, doi:10.1164/rccm.200712-18690C
   PubMed Web of Science ®Google Scholar
• Wilt T J, Bloomfield H E, Macdonald R, et al. Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med 2004; 164: 1427–1436
   PubMed Web of Science ®Google Scholar
• Agusti A GN. COPD, a multi component disease: implications for management. Resp Med 2005; 99: 670–682
   PubMed Web of Science ®Google Scholar
• Jeffery P K. Differences and similarities between chronic pulmonary disease and asthma. Clin Exp Allergy 1999; 29: 14–26
   PubMed Web of Science ®Google Scholar
• Hogg J C, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 2645–2653
   PubMed Web of Science ®Google Scholar
• Ronchi M C, Piragino C, Rosi E, et al. Role of sputum differential cell count in detecting airway inflammation in patients with COPD. Thorax 1996; 51: 1001–1004
   Google Scholar
• Riise G C, Ahlstedt S, Larsson S, et al. Bronchial inflammation in chronic bronchitis assessed by measurement of cell products in bronchial lavage. Thorax 1995; 5: 360–365
   Google Scholar
• Eriksson S. Pulmonary emphysema and α1-antitrypsin deficiency. AnnN Y Acad Sci 1991; 624: 1–6
   PubMedGoogle Scholar
• Thompson A B, Daughton D, Robbins R A, et al. Intraluminal airway inflammation in chronic bronchitis. Characterisation and correlation with clinical parameters. Am Rev Respir Dis 1989; 140: 1527–1537
   PubMed Web of Science ®Google Scholar
• Saetta M, Turato G, Facchini F M, et al. Inflammatory cells in the bronchial glands of smokers with chronic bronchitis. Am J Respir Crit Care Med 1997; 156: 1633–1639
   PubMed Web of Science ®Google Scholar
• Gamble E, Grootendorst D C, Hattotuwa K, et al. Airway mucosal inflammation in COPD is similar in smokers and ex-smokers:a pooled analysis. Eur RespirJ 2007; 30: 1–5
   PubMedGoogle Scholar
• Wouters E FM. Local and systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 26–33
   PubMedGoogle Scholar
• O'Shaughnessy T C, Ansari T W, Barnes N C, et al. Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+T lymphocytes with FEV1. Am J Respir Crit Care Med 1997; 155: 852–857
   PubMed Web of Science ®Google Scholar
• Saetta M. CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 822–826
   PubMed Web of Science ®Google Scholar
• Stanescu D, Sanna A, Veriter C, et al. Airways obstruction, chronic expectoration and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils. Thorax 1996; 51: 267–271
   PubMed Web of Science ®Google Scholar
• Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease mortality. Am J Respir Crit Care Med 1996; 153: 1530–1535
   PubMed Web of Science ®Google Scholar
• Aronson D, Roterman J, Yigla M, et al. Inverse association between pulmonary function and C-reactive protein in apparently healthy subjects. Am J Repir Crit Care Med 2006; 174: 626–632
   PubMed Web of Science ®Google Scholar
• Shaaban R, Kony S, Driss F, et al. Change in C-reactive protein levels and FEV1 decline: a longitudinal population-based study. Resp Med 2006; 100: 2112–2120
   PubMed Web of Science ®Google Scholar
• Donaldson G C, Seemungal T A, Patel I S. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest 2005; 128: 1995–2004
   PubMed Web of Science ®Google Scholar
• Turato G, Zuin R, Miniati M, et al. Airway inflammation in severe chronic obstructive pulmonary disease: relationship with lung function and radiologic emphysema. Am J Respir Crit Care Med 2002; 166: 105–110
   PubMed Web of Science ®Google Scholar
• Agusti A, Soriano J B. Dynamic hyperinflation and pulmonary inflammation: a potentially relevant relationship?. Proc Am Thorac Soc 2007; 4: 522–526
   PubMedGoogle Scholar
• Saetta M, Ghezzo H, Wong Dong K, et al. Loss of alveolar attachments in smokers. A morphometric correlate of lung function impairment. Am Rev Respir Dis 1985; 132: 894–900
   PubMed Web of Science ®Google Scholar
• Retamales I, Elliott W M, Meshi B, et al. Amplification of inflammation in emphysema and its association with latent adenoviral infection. Am J Respir Crit Care Med 2001; 164: 469–473
   PubMed Web of Science ®Google Scholar
• Hole D J, Watt G C, Davey-Smith G, et al. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. Br MedJ 1996; 313: 711–751
   PubMed Web of Science ®Google Scholar
• Sin D D, Man S F. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases: The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003; 107: 1514–1519
   PubMed Web of Science ®Google Scholar
• Zhu J, Qui Y S, Majumdar S, et al. Exacerbations of bronchitis. Bronchial eosinophilia and gene expression for interleukin-4, interleukin-5 and eosinophil chemoattractants. Am J Respir Crit Care Med 2001; 164: 109–116
   Google Scholar
• Saetta M, Di Stefano A, Maestrelli P, et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 1994; 150: 1646–1652
   PubMed Web of Science ®Google Scholar
• Edwards M R, Johnson M, Johnston S L. Combination therapy: synergistic suppression of virus-induced chemokines in airway epithelial cells. Am J Respir Cell Mol Biol 2006; 34: 616–624
   PubMed Web of Science ®Google Scholar
• Dekhuijzen P NR, Aben K KH, Dekker I, et al. Increased exhalation of hydrogen peroxide in patients with stable and unstable COPD. Am J Respir Crit Care Med 1996; 154: 813–816
   PubMed Web of Science ®Google Scholar
• Wedzicha J A, Seemungal T A, MacCallum P K, et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost 2000; 84: 210–215
   PubMed Web of Science ®Google Scholar
• Donaldson G C, Seemungal T AR, Bhownik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847–852
   PubMed Web of Science ®Google Scholar
• Gan W Q, Man S F, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004; 59: 574–580
   PubMed Web of Science ®Google Scholar
• Mannino D M, Brown C, Giovina G A. Obstructive lung disease deaths in the United States from 1979 through 1993. An analysis using multiple-cause mortality data. Am J Respir Crit Care Med 1997; 156: 814–818
   PubMed Web of Science ®Google Scholar
• Sabit R, Bolton C E, Edwards P H, et al. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 1259–1265
   PubMed Web of Science ®Google Scholar
• Man S FP, Connett J E, Anthonisen N R, et al. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 2006; 61: 849–853
   PubMed Web of Science ®Google Scholar
• Pai J R, Pischon T, Ma J, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004; 351: 2599–2600
   PubMed Web of Science ®Google Scholar
• Rana J S, Mittleman M A, Sheikh J, et al. Chronic obstructive pulmonary disease, asthma and risk of type 2 diabetes in women. Diabetes Care 2004; 27: 2478–2484
   PubMed Web of Science ®Google Scholar
• Pradham A D, Manson J E, Rifai N, et al. C-reactive protein, interleukin-6 and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327–334
   PubMed Web of Science ®Google Scholar
• Hotamisligil G S. The role of TNF ∝ and TNF receptors in obesity and insulin resistance. J Intern Med 1999; 245: 621–625
   PubMed Web of Science ®Google Scholar
• Bernard S, Le Blanc P, Whittom F, et al. Peripheral muscle weakness in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158: 629–634
   PubMed Web of Science ®Google Scholar
• Agusti A G, Sauleda J, Miralles C, et al. Skeletal muscle apoptosis and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166: 485–489
   PubMed Web of Science ®Google Scholar
• De Godoy I, Donahoe M, Calhoun W J, et al, Elevated T NF. ∝ production by peripheral blood monocytes of weight-losing COPD patients. Am J Respir Crit Care Med 1996; 53: 633–637
   Google Scholar
• Seemungal T AR, Donaldson G C, Paul E A, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1418–1422
   PubMed Web of Science ®Google Scholar
• Spencer S, Jones P W. GLOBE study group. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 2003; 58: 589–593
   PubMed Web of Science ®Google Scholar
• Donaldson G C, Wedzicha J A. COPD exacerbations: 1. Epidemiology. Thorax 2006; 61: 164–168
   PubMed Web of Science ®Google Scholar
• Snoeck-Stroband J B, Postma D S, Lapperre T S, et al. Airway inflammation contributes to health status in COPD: a cross-sectional study. Respir Res 2006; 7: 140
   PubMed Web of Science ®Google Scholar
• Parr D G, White A J, Bayley D L, et al. Inflammation in sputum relates to progression of disease in subjects with COPD:a prospective descriptive study. Respir Res 2006; 7: 136
   PubMed Web of Science ®Google Scholar
• Keatings V S, Jatakanon A, Worsdell Y M, et al. Effects of inhaled and oral corticosteroids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997; 155: 542–548
   PubMed Web of Science ®Google Scholar
• Verhoeven G T, Hegmans JP JJ, Mulder P GH, et al. Effects of fluticasone in COPD patients with bronchial hyperresponsiveness. Thorax 2002; 57: 694–700
   PubMed Web of Science ®Google Scholar
• Hattotuwa K L, Gizycki M, Ansari T W, et al. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind placebo-controlled biopsy study. Am J Respir Crit Care Med 2002; 165: 1592–1596
   PubMed Web of Science ®Google Scholar
• Barnes N C, Qui Y S, Pavord I D, et al. Anti-inflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 2006; 173: 736–743
   PubMed Web of Science ®Google Scholar
• Bourbeau J, Christodoulopoulos P, Maltais F, et al. Effect of salmeterol/fluticasone combination on airway inflammation in COPD: a randomised trial. Thorax 2007; 62: 938–943
   PubMed Web of Science ®Google Scholar
• Gosman M ME, Lappere T S, Snoek-Stroband J B, et al. Effect of 6 months therapy with inhaled fluticasone propionate (FP) with or without salmeterol (S) on bronchial inflammation in COPD. Proc Am Thorac Soc 2006; 3: A111
   PubMedGoogle Scholar
• Sabit R, Bolton C E, Allanby C, et al. Arterial stiffness is reduced by combination inhaled corticosteroid/long-acting beta -2 agonist therapy in patients with COPD. Thorax 2007; 62: A142
   Web of Science ®Google Scholar
• Soyseth V, Brekke P H, Smith P, et al. Statin use is associated with reduced mortality in COPD. Eur Respir J 2007; 29: 279–283
   PubMed Web of Science ®Google Scholar
• Johnson M. Interaction between corticosteroids and β2-agonists in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 2004; 1: 200–206
   PubMedGoogle Scholar
• Adcock I M, Maneechotesuwan K, Usmani O. Molecular interactions between glucocorticoids and long-acting β2–agonists. J Allergy Clin Immunol 2002; 110: S261–S268
   PubMedGoogle Scholar
• Barnes P J. Molecular mechanisms of steroid action in asthma. J Allergy Clin Immunol 1997; 1: 159–168
   Google Scholar
• Haque R A, Johnson M, Adcock I M, et al. Addition of salmeterol to fluticasone prolongs the retention of glucocorticoid receptors within the nucleus of BEAS-2B cells and enhances downstream glucocorticoid effects. Proc Am Thorac Soc 2006; 3: A78
   Google Scholar
• Roth M, Johnson P R, Rudiger J J, et al. Interaction between glucocorticoids and β2-agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet 2002; 360: 1293–1299
   PubMed Web of Science ®Google Scholar
• Sarir H, Mortaz E, Karimi K, et al. Combination of fluticasone propionate and salmeterol potentiates the suppression of cigarette smoke-induced IL-8 production by macrophages. Eur J Pharmacol 2007; 571: 55–61
   PubMed Web of Science ®Google Scholar
• Tp Y, Ito M, Adcock I M, et al. Formoterol enhances anti-inflammatory effects of corticosteroids in peripheral blood mononuclear cells from COPD patients. Eur Respir J 2006; 28: 215S
   Google Scholar
• Haque R A, Torego A, Essilfie-Quaye, et al. Effect of salmeterol and fluticasone on glucocorticoid receptor translocation in sputum macrophages and peripheral blood mononuclear cells from patients with chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006; 3: A848
   Google Scholar
• Wedzicha J A, Calverely P MA, Seemungal T A, et al. The prevention of chronic pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008; 177: 19–26
   PubMed Web of Science ®Google Scholar
• Verbout N G, Lorton J K, Jacoby D B, et al. A functional role for muscarinic receptors on eosinophils in the airways. Proc Am Thorac Soc 2006; 3: A587
   Google Scholar
• Powrie D J, Wilkinson T MA, Donaldson G C, et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur RespirJ 2007; 30: 472–478
   PubMed Web of Science ®Google Scholar
• Decramer M, Celli B, Taskin D, et al. Clinical Trial Design Considerations in assessing long-term functional impacts of tiotropium in COPD: The UPLIFT trial. J COPD 2004; 1: 303–312
   PubMedGoogle Scholar
• Alexeeff S E, Litonjua A A, Sparrow D, et al. Statin use reduces decline in lung function. Am J Respir Crit Care Med 2007; 176: 742–747
   PubMed Web of Science ®Google Scholar